Affimed Presents Updated Clinical Data from Phase 1/2 Study
100% objective response rate and improvement in the rate of complete responses (CR) from 38% to 62% after a second cycle in 13 patients treated at the...
Source: globenewswire.com
Page 4 - Affimednv News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Affimednv . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Affimednv Today - Breaking & Trending Today
Affimed Presents Findings from the Dose-escalation Phase of
The recommended phase 2 dose was determined at 480 mgAFM24 has demonstrated a well-managed safety profilePharmacodynamic activity was observed at doses of...
Source: globenewswire.com